期刊文献+

多西他赛与奥沙利铂联合治疗复发性上皮性卵巢癌疗效评价 被引量:14

Therapeutic effect of docetaxel combined with oxaliplatin for treatment of recurrent epithelial ovarian cancer
在线阅读 下载PDF
导出
摘要 目的观察和评估多西他赛联合奥沙利铂方案治疗复发性上皮性卵巢癌的临床疗效及安全性。方法对病理证实为复发性上皮性卵巢癌患者36例进行化疗。给药方案为:多西他赛75mg/m2,静脉滴注1h,第1天;奥沙利铂100mg/m2,静脉滴注2h,第1天。每21d重复,至少治疗2个周期。结果接受治疗的36例患者均可评价疗效,完全缓解率为8.3%,部分缓解率为47.2%,总有效率55.6%。主要毒副反应为骨髓抑制和周围神经炎。结论多西他赛联合奥沙利铂化疗方案治疗复发性上皮性卵巢癌有较好的疗效,毒副反应轻,耐受性好,值得进一步临床研究推广。 Objective To evaluate the efficacy and safety of docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) for treatment of recurrent epithelial ovarian cancer. Methods Thirty-six patients with histologically confirmed recurrent epithelial ovarian cancer received chemotherapy with DTX and OXA. DTX at the dose of 75 mg/m^2 was administered on day 1 by intravenous infusion in 60 rain, followed by OXA at 100 mg/m^2 given by a 2 h infusion. The chemotherapy cycles were repeated every 21 days, and the patients received at least 2 cycles. Results All the patients were available for response evaluation, among whom 3 (8.3%) showed complete responses and 17 (47.2%) showed partial responses, with an overall response rate of 55.6%. The main adverse effects included hematological toxicities and peripheral neuropathy. Conclusion Combination of DTX and OXA produces good therapeutic effect with tolerable toxicity profile for treatment of recurrent epithelial ovarian cancer.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2009年第11期2319-2320,2323,共3页 Journal of Southern Medical University
关键词 复发性上皮性卵巢癌/药物治疗 多西他赛 奥沙利铂 recurrent epithelial ovarian cancer/drug therapy docetaxel oxaliplatin
  • 相关文献

参考文献11

  • 1Daly MB, Ozols RF. Symptoms of ovarian cancer-Where to set the bar[J]? JAMA, 2004, 291: 2755-6.
  • 2Harter P, du Bois A. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence [J]. Curr Opin Oncol, 2005, 17: 505-14.
  • 3Ferrandina G, Legge F, Salutari V, et al. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations[J]. Eur J Cancer, 2006, 42: 2296-302.
  • 4路虹,王建东,孔为民.多西他赛作为一线用药治疗卵巢癌研究进展[J].肿瘤防治杂志,2005,12(15):1194-1196. 被引量:21
  • 5Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial for carboplatin , and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Ontology Group Study [ J ]. J Clin Oncol, 2003, 21 (17): 3194-200.
  • 6Latorre A, DeLena M, Catino A, et al. Epithelial ovarian cancer: second and third line chemotherapy (review)[J ]. Int J Onto, 2002, 21(1): 179-86.
  • 7李艳芳,李孟达,刘富元,刘继红,李俊东,黄永文.草酸铂治疗上皮性卵巢癌[J].癌症进展,2003,1(1):50-52. 被引量:2
  • 8Eriguchi M, Osada I, Fujii X, et al. Pilot study for preoperative administration of L-OHP to patients with advanced scirrhous type gastric cancer[J]. Biomed Pharmacother, 1997, 51(5): 217-20.
  • 9唐步坚,李力.复发上皮性卵巢癌的化学药物治疗[J].国际肿瘤学杂志,2005,32(1):68-71. 被引量:7
  • 10江楠,谢榕,林玉珍.多西紫杉醇与奥沙利铂联合化疗治疗45例复发性上皮性卵巢癌的近期疗效观察[J].福建医药杂志,2007,29(3):132-133. 被引量:4

二级参考文献52

  • 1路虹,王建东,孔为民.多西他赛作为一线用药治疗卵巢癌研究进展[J].肿瘤防治杂志,2005,12(15):1194-1196. 被引量:21
  • 2Piccart M J, Gore M, Ten Bokkel Huinink W, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer[J]. J Natl Cancer Inst, 1995, 87(9):676-681.
  • 3Markman M, Kennedy A, Webster K, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum[J]. J Clin Oncol,2001, 19(7):1901-1905.
  • 4Verschraegen C F, Sittisomwong T, Kudelka A P, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma[J]. J Clin Oncol, 2000, 18(14):2733-2739.
  • 5Rose P G, Blessing J A, Ball H G, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2003, 88(2):130-135.
  • 6Berkenblit A, Tung N, Kim Y, et al. Phase I trial of docetaxel, carboplatin, and gemcitabine as first line therapy for patients with high risk epithelial tumors of mullerian origin[J]. Gynecol Oncol,2003, 89(3):486-493.
  • 7Pfisterer J, du Bois A, Wagner U, et al. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group[J]. Gynecol Oncol, 2004, 92(3):949-956.
  • 8Vorobiof D A, Rapoport B L, Chasen M R, et al. Phase II clinical trial of carbopaltin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy [J]. Int J Gynecol Cancer, 2003, 13(3):287-291.
  • 9Dieras V, Guastalla J P, Ferrero J M, et al. A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study[J]. Cancer Chemother Pharmacol, 2004, 53(6): 489-495.
  • 10Neijt J P, Engelholm S A, Tuxen M K, et al. Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer[J]. J Clin Oncol, 2000, 18(17): 3084-3092.

共引文献28

同被引文献70

引证文献14

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部